Creating genetics-based infusion centers: a case study of two models.
In 1993, the first effective enzyme replacement therapy for a genetic disease, Ceredase (Genzyme Corporation, Cambridge, MA), was approved for use in patients with Gaucher disease. Over the next 13 years, enzyme replacement therapy became clinically available for the treatment of Fabry disease, mucopolysaccharidosis Type I, mucopolysaccharidosis Type II, mucopolysaccharidosis Type VI, and glycogen storage disease Type II. The development of enzyme replacement therapy to treat lysosomal storage diseases has resulted in an increasing number of genetic patients undergoing weekly or biweekly intravenous enzyme replacement therapy and an expanded role of the genetics team to include comprehensive care involving therapeutic intervention for lysosomal storage diseases. This article describes the development of two outpatient genetics-based infusion centers: the Northshore Genetics Infusion Clinic as part of the Children's Hospital of Wisconsin Lysosomal Diseases Treatment Center in conjunction with the Medical College of Wisconsin and the Emory Lysosomal Storage Disease Center for Genetic Infusions in the Emory University Department of Human Genetics.
Laney
Dawn J
DJ
Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
White
Amy L
AL
Rhead
William J
WJ
Fernhoff
Paul
P
D000554:Ambulatory Care Facilities / Q000191:economics* / Q000458:organization & administration* / Q000592:standards; D015316:Genetic Therapy; D006801:Humans; D007262:Infusions, Intravenous; D016464:Lysosomal Storage Diseases / Q000201:enzymology / Q000235:genetics / Q000628:therapy*; D000078329:Workforce